中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
17期
7-8
,共2页
可溶性Endoglin%宫颈癌%预后
可溶性Endoglin%宮頸癌%預後
가용성Endoglin%궁경암%예후
Soluble Endoglin%Cervical cancer%Prognosis
目的：研究宫颈癌患者血清可溶性Endoglin水平变化及其临床价值。方法应用酶联免疫吸附试验法(ELISA)对31例正常人(正常对照组)及63例宫颈癌患者(宫颈癌组)血清可溶性Endoglin水平进行检测,并比较38例宫颈癌患者根治手术前后血清可溶性Endoglin水平。结果宫颈癌组患者血清可溶性Endoglin水平(5.01±1.03)μg/L明显高于正常对照组(3.57±0.30)μg/L (P<0.01),血清可溶性Endoglin水平与宫颈癌患者临床分期有明显相关,与宫颈癌组患者年龄和病理类型无明显相关；Ⅳ期宫颈癌血清可溶性Endoglin水平(6.41±0.22)μg/L明显高于Ⅲ期(5.25±0.25)μg/L (P<0.01),Ⅲ期血清可溶性Endoglin水平明显高于Ⅱ期(4.38±0.26)μg/L (P<0.01),Ⅱ期血清可溶性Endoglin水平明显高于Ⅰ期(3.68±0.29)μg/L (P<0.05),Ⅰ期血清可溶性Endoglin水平与正常对照组比较,差异无统计学意义(P>0.05),血清可溶性Endoglin在宫颈癌患者根治术后的表达水平(3.85±0.71)μg/L明显低于术前(4.38±0.68)μg/L (P<0.01)。结论血清可溶性Endoglin表达水平可作为反映宫颈癌患者病情、疗效判断和预后评价的一个参考指标。
目的：研究宮頸癌患者血清可溶性Endoglin水平變化及其臨床價值。方法應用酶聯免疫吸附試驗法(ELISA)對31例正常人(正常對照組)及63例宮頸癌患者(宮頸癌組)血清可溶性Endoglin水平進行檢測,併比較38例宮頸癌患者根治手術前後血清可溶性Endoglin水平。結果宮頸癌組患者血清可溶性Endoglin水平(5.01±1.03)μg/L明顯高于正常對照組(3.57±0.30)μg/L (P<0.01),血清可溶性Endoglin水平與宮頸癌患者臨床分期有明顯相關,與宮頸癌組患者年齡和病理類型無明顯相關；Ⅳ期宮頸癌血清可溶性Endoglin水平(6.41±0.22)μg/L明顯高于Ⅲ期(5.25±0.25)μg/L (P<0.01),Ⅲ期血清可溶性Endoglin水平明顯高于Ⅱ期(4.38±0.26)μg/L (P<0.01),Ⅱ期血清可溶性Endoglin水平明顯高于Ⅰ期(3.68±0.29)μg/L (P<0.05),Ⅰ期血清可溶性Endoglin水平與正常對照組比較,差異無統計學意義(P>0.05),血清可溶性Endoglin在宮頸癌患者根治術後的錶達水平(3.85±0.71)μg/L明顯低于術前(4.38±0.68)μg/L (P<0.01)。結論血清可溶性Endoglin錶達水平可作為反映宮頸癌患者病情、療效判斷和預後評價的一箇參攷指標。
목적：연구궁경암환자혈청가용성Endoglin수평변화급기림상개치。방법응용매련면역흡부시험법(ELISA)대31례정상인(정상대조조)급63례궁경암환자(궁경암조)혈청가용성Endoglin수평진행검측,병비교38례궁경암환자근치수술전후혈청가용성Endoglin수평。결과궁경암조환자혈청가용성Endoglin수평(5.01±1.03)μg/L명현고우정상대조조(3.57±0.30)μg/L (P<0.01),혈청가용성Endoglin수평여궁경암환자림상분기유명현상관,여궁경암조환자년령화병리류형무명현상관；Ⅳ기궁경암혈청가용성Endoglin수평(6.41±0.22)μg/L명현고우Ⅲ기(5.25±0.25)μg/L (P<0.01),Ⅲ기혈청가용성Endoglin수평명현고우Ⅱ기(4.38±0.26)μg/L (P<0.01),Ⅱ기혈청가용성Endoglin수평명현고우Ⅰ기(3.68±0.29)μg/L (P<0.05),Ⅰ기혈청가용성Endoglin수평여정상대조조비교,차이무통계학의의(P>0.05),혈청가용성Endoglin재궁경암환자근치술후적표체수평(3.85±0.71)μg/L명현저우술전(4.38±0.68)μg/L (P<0.01)。결론혈청가용성Endoglin표체수평가작위반영궁경암환자병정、료효판단화예후평개적일개삼고지표。
Objective To research changes of soluble Endoglin level and its clinical significance in cervical cancer patients.MethodsEnzyme-linked immuno sorbent assay (ELISA) was applied for serum soluble Endoglin level detection in 31 normal people (normal control group) and 63 cervical cancer patients (cervical cancer group). Comparison was made on serum soluble Endoglin level in 38 cervical cancer patients before and after radical operation.ResultsCervical cancer patients had much higher serum soluble Endoglin level as (5.01±1.03)μg/L than (3.57±0.30)μg/L of the normal control group (P<0.01). Serum soluble Endoglin level was obviously related with clinical stage of cervical cancer patients, while it has no relationship with age and pathological type of cervical cancer patients. Stage Ⅳ cervical cancer had much higher serum soluble Endoglin level as (6.41±0.22)μg/L than (5.25±0.25)μg/L of stage Ⅲ (P<0.01); stage Ⅲ cervical cancer had much higher serum soluble Endoglin level than (4.38±0.26)μg/L of stage Ⅱ (P<0.01); stage Ⅱ cervical cancer had much higher serum soluble Endoglin level than (3.68 ±0.29)μg/L of stage Ⅰ (P<0.05). The difference of serum soluble Endoglin level between stage Ⅰ and normal control group had no statistical significance (P>0.05). Serum soluble Endoglin level in cervical cancer patients after operation was obviously lower as (3.85±0.71)μg/L than (4.38±0.68)μg/L before operation (P<0.01).ConclusionExpression level of serum soluble Endoglin can be used as a referring index for showing disease status, judging curative effect and evaluating prognosis in cervical cancer patients.
